• Astute, a US-based imaging-guided therapy provider has acquired Egypt-based healthtech startup and AI-powered screening provider DilenyTech for an undisclosed value. The acquisition will enable Astute to leverage Dileny's tech stack to improve its current products and expand its suite of offerings.
• Founded in 2018 by Ahmed Ehab Mahmoud, DilenyTech develops solutions for medical imaging analysis, breast cancer risk assessment, and synoptic reporting.
• Earlier in 2021, Dileny was awarded a $160,000 non-equity grant. 

Press release

US-based imaging-guided therapy provider Astute Imaging LLC has announced its acquisition of Cairo-based HealthTech and AI-powered deep technology screening provider DilenyTech.  The acquisition will enable Astute Imaging to leverage the power of AI to improve its current offering, expand services and develop innovative solutions in the medical imaging domain.

Dileny Technologies (DilenyTech) is a cutting-edge startup that develops and deploys innovative AI technologies to empower radiology workflow. It focuses on medical imaging analysis applications, breast cancer risk assessment, and structured reporting for several medical applications. This acquisition comes as a big step for the Cairo-based startup as it merges with Astute Imaging the healthcare IT solutions company focusing on developing disruptive AI solutions to advance image-guided therapy and procedure planning for cardiovascular and interventional radiology.

Astute Imaging is focusing on adopting state-of-the-art AI and cloud technologies to advance its unique patented imaging software and enable precision medicine for healthcare providers and device companies. DilenyTech developed several vendor-neutral AI proprietary technologies for radiology workflow with a special focus on women’s health. The company was recently granted a US patent for its novel AI technology in medical imaging and provided its services to top-tier international healthcare companies and medical organizations. "This strategic acquisition of DilenyTech will enable Astute Imaging to expedite the development of an AI-driven image-guided therapy platform and add more automation to our imaging services and procedure planning solutions,” Wael Elseaidy, co-founder and CEO of Astute Imaging, stated. “Empowering our surgery planning and patient follow-up imaging platforms with AI will help our customers and medical imaging stakeholders to provide more patient-centric proactive services."

Astute Imaging is planning to launch an AI-powered tracking application for the aorta to provide proactive patient-centric services for providers. Whereas for the medical device companies, Astute Imaging is planning to enable its imaging core lab and procedure planning services with AI to allow seamless workflow and device tracking for the medical device industry. “This acquisition will help Astute Imaging to expedite the introduction of AI into its cloud-based platform for image-guided therapy and workflow automation utilizing millions of procedure data assets to drive faster and enhanced services.” Ewald de Vries, co-founder, and Astute imaging CTO indicated. “Incorporating AI into our cloud-based alert management system and creating data-driven predictive algorithms for procedure planning will make our offering very powerful and unique.”

Astute imaging is also planning to develop and offer predictive models for cardiovascular case planning and to expand into other areas such as women's health, and cancer treatments. Predictive models will help companies to get better insights about future enhancements for interventional devices for image-guided procedures, especially in the cardiovascular and cancer domains. “We are excited to be part of Astute Imaging’s amazing team and adopt our expertise and technologies to build reliable AI technologies for imaging-guided therapy,” said Ahmed Ehab Mahmoud, DilenyTech founder and innovation director who will be joining Astute Imaging’s founding team and managing the imaging operations. “We have applied our technologies successfully in the area of breast imaging and we look forward to expanding our AI pipeline to other imaging areas such as thyroid, liver, and gynecology as well as cardiovascular 3D imaging and procedural planning. We believe Astute Imaging will be a game-changer for healthcare providers and device companies.”